Cargando…

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding

OBJECTIVES: Outpatient treatment of acute venous thromboembolism (VTE) requires the selection of patients with a low risk of bleeding during the first few weeks of anticoagulation. The accuracy of four systems, originally derived for predicting bleeding in VTE treated with vitamin K antagonists (VKA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kline, Jeffrey A., Jimenez, David, Courtney, D. Mark, Ianus, Juliana, Cao, Lynn, Lensing, Anthonie W.A., Prins, Martin H., Wells, Philip S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066651/ https://www.ncbi.nlm.nih.gov/pubmed/26765080 http://dx.doi.org/10.1111/acem.12865

Ejemplares similares

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Immediate Discharge and Home Treatment With Rivaroxaban of Low‐risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One‐year Preplanned Analysis
por: Beam, Daren M., et al.
Publicado: (2015)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Bleeding risk assessment for venous thromboembolism prophylaxis
por: Chindamo, Maria Chiara, et al.
Publicado: (2021)

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2019)

COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding
por: Demelo-Rodriguez, Pablo, et al.
Publicado: (2023)

Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk
por: Muster, Viktoria, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding
por: Johnsen, Håkon S., et al.
Publicado: (2019)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Risk assessment of venous thromboembolism and bleeding in COVID‐19 patients
por: Wang, Lan, et al.
Publicado: (2022)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography
por: Zalewski, Jaroslaw, et al.
Publicado: (2020)

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
por: Kang, Hye-Rim, et al.
Publicado: (2023)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Lower Gastrointestinal Bleeding And Risk of Gastrointestinal Cancer
por: Viborg, Søren, et al.
Publicado: (2016)

Risk Factors of Unfavorable Outcomes, Major Bleeding, and All-Cause Mortality in Patients with Venous Thromboembolism
por: Lee, Han Young, et al.
Publicado: (2021)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
por: Klok, Frederikus A., et al.
Publicado: (2019)

Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID‐19
por: Woller, Scott C., et al.
Publicado: (2022)

Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia
por: Hisada, Yohei, et al.
Publicado: (2023)

Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)

The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events
por: Sharman Moser, Sarah, et al.
Publicado: (2021)

Through thick and thin: Risk of venous thromboembolism vs bleeding after abdominal transplant
por: Whitrock, Jenna N., et al.
Publicado: (2023)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Comparison of Performances among Four Bleeding-Prediction Scores in Elderly Cancer Patients with Venous Thromboembolism
por: Xi, Shaozhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_okr7n3njvk29qfhrlbvcjav4q4